Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Nears Astra AI Model Launch With Safety Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
France Targets Shein, Temu With Fast-Fashion Fees 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Add as a preferred source on Google
WALTHAM, Mass., March 05, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Cowen and Company 38th Annual Health Care Conference
Monday, March 12, 2018 at 1:30 p.m. ET
Location: Boston, MA - Barclays Global Healthcare Conference
Wednesday, March 14, 2018 at 3:50 p.m. ET
Location: Miami, FL - Needham 17th Annual Healthcare Conference
Tuesday, March 27, 2018 at 8:30 a.m. ET
Location: New York, NY
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
